US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

13.17

0.0000

Post-market: 13.170.00000.00%16:10 EDT

Volume:105.44K

Turnover:1.38M

Market Cap:648.60M

PE:-2.92

High:14.13

Open:13.15

Low:12.75

Close:13.17

52wk High:17.82

52wk Low:8.75

Shares:49.25M

Float Shares:13.84M

Volume Ratio:0.58

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:6.04

PE(LYR):-0.08

Loading ...

Overview Company News Filings

European Equities Traded in the US as American Depositary Receipts Decline Friday

MT Newswires Live

Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment

Agomab announces NOV-ERA study design

Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease

Agomab Announces Design of Nov-Era Phase 2B Study With Ontunisertib in Fibrostenosing Crohn’s Disease

THOMSON REUTERS

AgomAb Therapeutics Initiated at Buy by HC Wainwright & Co.

Agomab initiated with a Buy at H.C. Wainwright

Agomab Therapeutics Nv : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $35

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Agomab Therapeutics holds annual general meeting, backs board reappointments

Press Release: Agomab Announces Results of Annual General Meeting

Wall Street Analysts Are Bullish on Top NA Picks

Press Release: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab FY25 net loss widens 35% to EUR 62.5 million

Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041

Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

THOMSON REUTERS

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement

Agomab Therapeutics NV CEO and Director Tim Jasper Knotnerus Files Initial Beneficial Ownership Statement

Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/AGMB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":13.17,"timestamp":1788206400000,"preClose":13.17,"halted":0,"volume":105442,"hourTrading":{"tag":"盘后","latestPrice":13.17,"preClose":13.17,"latestTime":"16:10 EDT","volume":381,"amount":5017.7699999999995,"timestamp":1788207004825,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Post-Mkt","change":0,"latestTime":"08-31 18:35:27 EDT","open":13.15,"high":14.13,"low":12.75,"amount":1377528,"amplitude":0.104784,"askPrice":14.96,"askSize":100,"bidPrice":5.24,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":13.17,"preHourTrading":{"tag":"盘前","latestPrice":13.6,"preClose":13.17,"latestTime":"09:28 EDT","volume":96,"amount":1307.040096,"timestamp":1788182880007,"change":0.43,"changeRate":0.03265,"amplitude":0.002278},"postHourTrading":{"tag":"盘后","latestPrice":13.17,"preClose":13.17,"latestTime":"16:10 EDT","volume":381,"amount":5017.7699999999995,"timestamp":1788207004825,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.584563},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.584563,"shares":49248000,"dividePrice":0,"high":14.13,"amplitude":0.104784,"preClose":13.17,"low":12.75,"week52Low":8.75,"pbRate":"6.04","week52High":17.82,"institutionHeld":0,"latestPrice":13.17,"committee":0.333333,"eps":-4.51426,"divideRate":0,"volume":105442,"delay":0,"ttmEps":-4.51426,"open":13.15,"prevYearClose":16,"prevWeekClose":13.17,"prevMonthClose":12.87,"prevQuarterClose":12.98,"fiveDayClose":12.82,"twentyDayClose":13.52,"sixtyDayClose":11.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-08-28","current":-2.917422,"percent":0.539568,"low":-14.725744,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"high":-6.52172,"avg":-9.647879,"sd":2.254804,"marketCap":681591974},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974}],"updateTime":1788215727594},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2646366992","title":"European Equities Traded in the US as American Depositary Receipts Decline Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2646366992","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646366992?lang=en_us&edition=fundamental","pubTime":"2026-06-26 23:06","pubTimestamp":1782486382,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower Friday morning, decreasing 0.4% to 1,883.22 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech companies Evaxion  and Abivax , which gained 5.4% and 4.5% respectively. They were followed by healthcare firm Grifols  and drink and brewing giant Anheuser-Busch Inbev , which added 1.4% and 1.1%, respectively.The decliners from continental Europe were led by Agomab Therapeutics  and steel producer ArcelorMittal , which fell 3.9% and 3.5% respectively. They were followed by energy company Equinor , which was down 1.3%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways  and Autolus Therapeutics , which rose 5.6% and 2.8% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm  and Barclays , which shed 4% and 1.3% respectively.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4543","BK4207","ADRU","IE00BMPRXN33.USD","BK4006","ABVX","MT","ARMU","BK4007","BK4158","ARMW","BK4561","ARMG","IE00BMPRXR70.SGD","BK4141","BK4585","BK4609","BK4588","LU0081259029.USD","BK4521","LU2543165471.USD","EQNR","LU0348723411.USD","AGMB","BCS","EVAX","LU1232071149.USD","BK4201","AUTL","IE00BMPRXQ63.HKD","BUD","GRFS","BK4139","CMPS","ARM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645915854","title":"Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645915854","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645915854?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:14","pubTimestamp":1782249240,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reached alignment with the Food and Drug Administration on the design of a Phase 2b study for patients with Crohn's disease who develop intestinal narrowings that can block food and often lead to surgery.The study will test Agomab's experimental pill, ontunisertib, against placebo in up to 320 adults, the Belgium-based company said Tuesday. Doctors will check at 24 weeks whether a scope can pass through the narrowed section of the intestine, which is a practical way to see if the blockage is easing. The trial will also follow patients to 52 weeks to track longer-term outcomes.Agomab said the protocol has been filed with the FDA and cleared a central ethics review in the U.S., and the study has Health Canada approval. The company has also submitted clinical trial applications in Europe and parts of Asia. The first patient is expected to be dosed in the second half of this year.Crohn's is a chronic progressive disease of the gastrointestinal tract. About 46% of all pa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","AGMB","ADC","BK4080","LABU","BK4231","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645485922","title":"Agomab announces NOV-ERA study design","url":"https://stock-news.laohu8.com/highlight/detail?id=2645485922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645485922?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:18","pubTimestamp":1782245926,"startTime":"0","endTime":"0","summary":"Agomab (AGMB) announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal-restricted ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4179","BK4007","NOV","LU0061475181.USD","LU1878469433.USD","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859954","title":"Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859954","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859954?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:06","pubTimestamp":1782245172,"startTime":"0","endTime":"0","summary":"Agomab secured FDA alignment on the Phase 2b NOV-ERA study design for ontunisertib in fibrostenosing Crohn’s disease.The protocol cleared central IRB review in the U.S. and received Health Canada authorization.First patient dosing is targeted for the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL3YCkJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AGMB","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","BK4007","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859691","title":"Agomab Announces Design of Nov-Era Phase 2B Study With Ontunisertib in Fibrostenosing Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859691?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:05","pubTimestamp":1782245100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA9TGKXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029722","title":"AgomAb Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029722","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029722?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:11","pubTimestamp":1782126660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:11 ET (11:11 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645026819","title":"Agomab initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2645026819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645026819?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:05","pubTimestamp":1782122738,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio initiated coverage of Agomab (AGMB) with a Buy rating and $35 price target The firm says both of Agomab’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025530","title":"Agomab Therapeutics Nv : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645025530?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:01","pubTimestamp":1782122485,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nAZN4T3J2A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DAL","KLAG","LGN","INCY","FTH","LINT","MRNX","GLW","BILL","DCH","KR","CHRD","MUU","MTDR","ENPH","INTC","ABVX","NBIX","VC","LQDA","HCA","ARMK","ALT","BWXT","BWIN","KLAC","LRCU","AAL","MRK","ALGM","CNXU","DFTX","DAR","FPS","INTW","KMX","MRNA","MULL","MU","AALG","LRCX","APGE","FMC","AMRZ","AGMB","BYD","FANG","MRNY","AMAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638550503","title":"Agomab Therapeutics holds annual general meeting, backs board reappointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2638550503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638550503?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:00","pubTimestamp":1779872448,"startTime":"0","endTime":"0","summary":"Agomab held its annual general meeting on May 26, 2026.Shareholders adopted the statutory financial statements for the year ended Dec. 31, 2025.Shareholders granted discharge to current and former directors, plus the statutory auditor, for duties performed in 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8BnFDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4112","SG9999014039.USD","IE00BN0W2V16.EUR","BK4007","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","AGMB","LU0314104364.USD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4588","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638950336","title":"Press Release: Agomab Announces Results of Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638950336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638950336?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:00","pubTimestamp":1779872400,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, May 27, 2026 -- Agomab Therapeutics NV  , a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting  held on Tuesday, May 26, 2026.-- Approval of the statutory financial statements for the financial year. -- Discharge to the current and former members of the Board of Directors and. the statutory auditor in respect of the performance of their respective. duties during the financial year ending on December 31, 2025.-- Reappointment of Mr. Ohad Hammer as a member of the Board of Directors. -- Reappointment of Mr. Tim Knotnerus as a member of the Board of Directors. Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab's product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGM","BK4007","BK4229","BK4195","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076558","title":"Wall Street Analysts Are Bullish on Top NA Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076558?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:01","pubTimestamp":1779109297,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on AgomAb Therapeutics NV ADR (AGMB) and Standard Chartered (SC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-8?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-na-picks-blurbs-news-8?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB","BLSG","SCBFY","BK4112","BLSX","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629690438","title":"Press Release: Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2629690438","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629690438?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:14","pubTimestamp":1776982440,"startTime":"0","endTime":"0","summary":"-- Cash and Cash Investments at December 31, 2025 of EUR116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering  Expected to Extend Cash Runway into First Half of 2029 --. Pierre Kemula, Chief Financial Officer of Agomab, added, \"Thanks to the $208 million in gross proceeds raised from our IPO in February 2026, we are well-capitalized and we expect our cash reserves to last into the first half of 2029. With major milestones approaching later this year, we remain laser-focused on delivering on our corporate and clinical strategy.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGM","BK4007","BK4229","BK4195","IPO","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629866477","title":"Agomab FY25 net loss widens 35% to EUR 62.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629866477","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629866477?lang=en_us&edition=fundamental","pubTime":"2026-04-24 05:18","pubTimestamp":1776979127,"startTime":"0","endTime":"0","summary":"Agomab posted a net loss of EUR 62.5 million for fiscal 2025, widening 35%.Operating loss widened 23% to EUR 59.3 million.Research and development expenses climbed 24% to EUR 48.9 million, due to progress in clinical testing for ontunisertib and AGMB-447.Other operating income jumped 68% to EUR 2.4 million.Cash, cash equivalents and cash investments totaled EUR 116.5 million at Dec. 31, 2025; existing liquidity plus IPO proceeds expected to fund operations into the first half of 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLbZTC6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622085155","title":"Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2622085155","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622085155?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:01","pubTimestamp":1774522892,"startTime":"0","endTime":"0","summary":"Agomab said the USPTO granted U.S. Patent No. 12,577,230 covering the composition of matter of AGMB-447.AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5  in a Phase 1b study for idiopathic pulmonary fibrosis.The company said the patent provides U.S. IP protection through at least 2041, excluding potential patent term extensions.CEO Tim Knotnerus said Agomab expects results from the idiopathic pulmonary fibrosis patient cohort of the Phase 1b study later this year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2yYlHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","AGMB","BK4007","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588","IE00BN0W2W23.USD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","BK4585","LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622212859","title":"Agomab Receives U.S. Patent for Agmb-447, Its Inhaled Lung-Restricted Small Molecule Inhibitor of Alk5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622212859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622212859?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA6BRHW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851262","title":"Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851262","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851262?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262841/0/en/Agomab-Receives-U-S-Patent-for-AGMB-447-its-Inhaled-Lung-restricted-Small-Molecule-Inhibitor-of-ALK5-in-Development-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","LU1169589451.USD","BK4588","IP","LU1487256676.USD","IE00B3T34201.USD","LU1481599808.USD","AGMB","BK4585","BK4007","LU1481600234.SGD","LU1169590202.USD","BK4136"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620473264","title":"Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620473264","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620473264?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:03","pubTimestamp":1773864192,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership for director David Epstein. Epstein disclosed stock options to buy 770,671 common shares at an exercise price of USD 2.81. He also reported stock options to buy 217,295 common shares at an exercise price of USD 5.26. In addition, Epstein reported stock options to buy 38,843 common shares at an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2nntt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620644382","title":"Agomab Therapeutics NV CEO and Director Tim Jasper Knotnerus Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620644382","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620644382?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:03","pubTimestamp":1773864183,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership by Tim Jasper Knotnerus, a director and chief executive officer. The filing listed 10,823 common shares held directly by Knotnerus. It also reported 34,394 common shares held indirectly through TJK Life Sciences. The filing disclosed stock options covering 683,248 common shares with an exercise price of USD 0.0005.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbllKNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264410","title":"Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264410","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264410?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:02","pubTimestamp":1773864177,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reported an initial statement of beneficial ownership by director Ohad Hammer. The filing listed a stock option for 27,921 common shares. The option has an exercise price of USD 14.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL98LGY6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":52,"code":"91000000","status":"200"}]}}